Radiopharm Theranostics (ASX:RAD) secured approval from the Data and Safety Monitoring Committee (DSMC) to proceed to the next dose in its first phase clinical trial for radiotherapeutic asset 177Lu-RAD204 in patients with PD-L1 positive advanced cancers, according to a Tuesday filing with the Australian bourse.
The DSMC confirmed the safety, pharmacokinetic, and biodistribution data of the first group of four patients treated with 30 millicurie of 177Lu-RAD204, allowing the study to continue without modifications, the filing said.
The second group will start at 60 millicurie of Lu177, expected to enroll by the middle of the year, and expand to multiple tumor types, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。